Earlier-onset, more severe neurodegeneration in PGRN KO mice with a decreased dose of D409V Gba1MOLECULAR GENETICS AND METABOLISMIF3.52023-02-010PRE
Therapies for lysosomal storage diseases: Principles, practice, and prospects for refinements based on evolving scienceMOLECULAR GENETICS AND METABOLISMIF3.52022-09-017PRE
Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensusMOLECULAR GENETICS AND METABOLISMIF3.52022-02-0117OAAI
GOAL-GD: A smartphone application to enhance patient engagement in a real-world study of treatment switching in patients with Gaucher disease type 1MOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
Gaucher disease: Basic and translational science needs for more complete therapy and managementMOLECULAR GENETICS AND METABOLISMIF3.52021-02-0139OAAI
Gaucher disease and SARS-CoV-2 infection: Emerging management challengesMOLECULAR GENETICS AND METABOLISMIF3.52020-07-0126OAAI
Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher diseaseHUMAN MOLECULAR GENETICSIF3.22019-08-029OAAI
Combination of acid β-glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotypeSCIENTIFIC REPORTSIF3.92019-04-0315OAAI
An unexpected player in Gaucher disease: The multiple roles of complement in disease developmentSEMINARS IN IMMUNOLOGYIF7.82018-06-0135PREAI
LAL (Lysosomal Acid Lipase) Promotes Reverse Cholesterol Transport In Vitro and In VivoARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGYIF7.42018-05-0124OAAI
Pharmacogenetics of Antiepileptic Drug Efficacy in Childhood Absence EpilepsyANNALS OF NEUROLOGYIF7.72017-03-2551OAAI
Glucosylceramide partnership with immunological villain in Gaucher diseaseMOLECULAR GENETICS AND METABOLISMIF3.52017-01-010PREAI
Lysosomal acid lipase deficiency: Expanding differential diagnosisMOLECULAR GENETICS AND METABOLISMIF3.52017-01-0131PREAI
Ten plus one challenges in diseases of the lysosomal systemMOLECULAR GENETICS AND METABOLISMIF3.52017-01-014PREAI
Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease miceHUMAN MOLECULAR GENETICSIF3.22016-09-2037OAAI
Options to consider when treating lysosomal acid lipase deficiency ResponseJOURNAL OF CLINICAL LIPIDOLOGYIF4.62016-09-011PREAI
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher DiseaseMOLECULAR THERAPYIF122016-06-0185OAAI
Platelets Transfusion New Role as Brain Therapeutics for Acute Neuronopathic Gaucher DiseaseMOLECULAR THERAPYIF122016-05-010OAAI
Immune cells attack and neurodegeneration in Gaucher diseaseMOLECULAR GENETICS AND METABOLISMIF3.52016-02-011PREAI
Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse modelHUMAN MOLECULAR GENETICSIF3.22015-09-2943OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向